Patient Considerations When Selecting Disease-Modifying Therapy in Multiple Sclerosis

RELEASE DATE: October 21, 2020


This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and CMEology.

This activity is supported by educational grants from Biogen, Bristol Myers Squibb, and EMD Serono.

Target Audience

This activity is designed to meet the educational needs of neurologists, advanced practice neurology clinicians, neurology nurses, pharmacists, and other members of the health care professional team involved in the care of patients with multiple sclerosis.

Program Overview

With more than a dozen disease-modifying therapies (DMTs) now available for multiple sclerosis (MS), treatment selection has become more complex. Clinicians need to know how and when to switch DMTs and ways to optimize outcomes in different situations, including pregnancy and breastfeeding. In this activity, expert faculty will discuss the latest options and best practices in DMT selection and how shared decision-making can be used to help patients meet their treatment goals. Management strategies and DMT considerations for pre-conception, pregnancy, and breastfeeding will also be explored. Two comic-style case scenarios and video commentary from two patients with MS will be presented to illustrate challenges encountered in clinical practice.

Learning Objectives

After completing this activity, participants will be better able to:

  • Evaluate the key considerations related to patient DMT selection
  • Employ optimal strategies for patient communication when starting or switching a DMT
  • Apply strategies for optimal selection and use of DMTs before, during, and after pregnancy
  • Define the elements of an effective shared decision-making process in DMT selection


Patricia K. Coyle, MD
Professor of Neurology and Vice Chair
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Patricia M. Melville, RN, MSN, NP-C, MSCN
Clinical Instructor, Department of Neurology
SUNY at Stony Brook
Stony Brook MS Comprehensive Care Center
Stony Brook, NY

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and CMEology. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
The CMSC designates this enduring material for 1.0 continuing education nursing credit (1.0 in the area of pharmacology).

Pharmacists Credit

This knowledge-based activity (JA4008165-9999-20-056-H01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.


Disclosures of Conflicts of Interest

It is the policy of CMSC and CMEology to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Patricia K. Coyle, MD
Consultant Fees: Accordant, Alexion, Biogen Idec, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, TG Therapeutics; Research Grants: Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis

Patricia M. Melville, RN, MSN, NP-C, MSCN
Consultant Fees: Biogen Idec, Celgene/Bristol Myers Squibb, EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzvme,

Laurie Scudder, DNP, NP has served as both a planner and reviewer for this activity and has disclosed no relevant financial relationships.

June Halper, MSN, APN-C, MSCN, FAAN (Planner and Reviewer) has disclosed no relevant financial relationships.

CMEology planners have no relationships to disclose.

The staff at CMSC have disclosed no relevant financial relationships.

Disclosure of Unlabeled Use

CMSC and CMEology require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


To view the CMSC Privacy Policy, visit our website at

Contact Information

If you have any questions about this CE activity, please contact The CMSC at [email protected] or CMEology at: [email protected].

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts